What is an ImmTAC® molecule?
ImmTAC® (Immune mobilising monoclonal TCRs against cancer) molecules are a new class of bi-specific biologics designed to overcome the limitations of other immuno-oncology agents by combining a T cell receptor (TCR)-targeting system with an anti-CD3 effector function to activate a highly potent and specific T cell response to cancer cells.
ImmTAC® molecules have the potential to access >90% of target antigens
One of the greatest challenges in immunotherapy is the identification of new and safe target antigens. Antibody-based therapies, including bi-specifics and CAR-T cells, recognise cell surface antigens, which account for as low as ~10% of potential disease targets.
TCRs are naturally optimised to recognise intracellular antigens presented on the cell surface as peptide-HLA complexes, permitting access to potentially nine-fold more targets than antibody-based therapies.
- ImmTAC® molecules; Immune mobilising monoclonal TCRs Against Cancer
- TILs; Tumour Infiltrating Lymphocytes
- CAR-T cell; Chimeric Antigen Receptor T cell
- T and Ab; Tetravalent bi-specific Ab
- DART; Dual Affinity Re-Targeting Ab
- BiTE; bi-specific T cell engager
- HLA; Human Leukocyte Antigen
Soluble ImmTAC® molecules also offer advantages in manufacturing and administration over cellular TCR-based platforms.